Tuesday, January 12, 2021 10:07:03 AM
Tue, January 12, 2021, 6:00 AM PST
ENGLEWOOD, Colo., Jan. 12, 2021 /PRNewswire/ -- Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in manufacturing and selling non-invasive medical devices for pain management, stroke rehabilitation, cardiac monitoring and neurological diagnostics, today announced orders for Q4 2020.
Thomas Sandgaard, CEO of Zynex said: "We concluded 2020 with strong orders and posted 117% year over year growth. For the full year orders grew 96% which in the midst of a pandemic is a very solid result. Our sales team continues to do a great job as they deal with unforeseen challenges brought about by COVID-19.
During Q4, we continued to aggressively hire sales reps as we exceeded 500 sales reps at year-end. We expect to have approximately 600 sales reps in the U.S. by the end of 2021.
The Company is confirming its previous revenue estimate for the fourth quarter of 2020 of between $25.5 and $26.5 million and is increasing its fourth quarter Adjusted EBITDA estimate to between $3.1 and $4.1 million. The previous estimate was between $2.3 and $3.3 million.
The Company's full year 2020 revenue estimate is between $80 and $81 million. The revenue estimate is approximately 76% to 78% above last year's full year revenue of $45.5 million.
2020 full year estimated Adjusted EBITDA is estimated between $13.3 to $14.3 million which is 10% to 18% above 2019's full year Adjusted EBITDA of $12.1 million.
Our prescription-strength NexWave device is a healthy alternative to prescribing opioids as the first line of defense when treating pain. We continue to add additional sales reps in territories throughout the U.S. that we have not covered previously.
We continue to advocate for pain patients, and for physicians to prescribe our NexWave technology as the first line of defense in treating chronic and acute pain without side effects. We are dedicated to promoting our technology in an effort to remove patient addiction and other side effects from prescription opioids."
Recent PAYS News
- Paysign to Host First Quarter 2024 Earnings Call • Business Wire • 04/09/2024 08:30:00 PM
- Paysign, Inc. to Sponsor the 2024 International Plasma Protein Congress April 16-17 • Business Wire • 03/14/2024 08:30:00 PM
- Paysign, Inc. Reinforces Payment Processing Acumen With New Executive Hire • Business Wire • 03/13/2024 08:30:00 PM
- Paysign, Inc. to Sponsor the 2024 Gene Therapy for Rare Disorders Conference March 26-29 • Business Wire • 03/12/2024 08:30:00 PM
- Paysign Inc. to Sponsor the 2024 ACCESS USA Conference March 19-21 • Business Wire • 03/11/2024 08:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/07/2024 11:22:09 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/07/2024 11:14:01 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/05/2024 01:07:20 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/04/2024 12:51:22 PM
- Paysign to Host Fourth Quarter and Full Year 2023 Earnings Call • Business Wire • 02/27/2024 09:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/21/2024 11:01:31 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/21/2024 10:55:56 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/12/2024 05:36:58 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/06/2024 11:50:15 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/06/2024 11:44:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/31/2024 11:57:43 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/31/2024 11:49:18 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/26/2024 12:50:43 AM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 01/26/2024 12:26:53 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/26/2024 12:03:20 AM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 01/24/2024 09:05:27 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/08/2023 12:56:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/07/2023 09:00:10 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/02/2023 09:44:16 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM